Showing posts with label Discovery. Show all posts
Showing posts with label Discovery. Show all posts

Saturday, September 10, 2011

Scientists induce hibernation at will: Discovery puts scientists closer to human application

ScienceDaily (July 26, 2011) — Hibernation is an essential survival strategy for some animals and scientists have long thought it could also hold promise for human survival. But how hibernation works is largely unknown. Scientists at the University of Alaska Fairbanks have successfully induced hibernation at will, showing how the process is initiated. Their research is published in the July 26 issue of The Journal of Neuroscience.See Also:Health & MedicineInsomnia ResearchControlled SubstancesHuman BiologyPlants & AnimalsBiologyAnimalsNatureStrange ScienceReferenceParasympathetic nervous systemExcitotoxicity and cell damageNeurotransmitterAntifreeze protein

A hibernating animal has a reduced heart rate and blood flow similar to a person in cardiac arrest, yet the hibernator doesn't suffer the brain damage that can occur in people. "Understanding the neuroprotective qualities of hibernating animals may lead to development of a drug or therapy to save people's lives after a stroke or heart attack," said Kelly Drew, senior author and UAF professor of chemistry and biochemistry in the Institute of Arctic Biology.

Hibernating animals survive by severely reducing their metabolism, a condition called torpor, in which oxygen consumption can fall to as low as one percent of resting metabolic rate and core body temperature to near or below freezing temperatures.

Arctic ground squirrels, like all animals and people, produce a molecule called adenosine that slows nerve cell activity. "When a squirrel begins to hibernate and when you feel drowsy it's because adenosine molecules have attached themselves to receptors in your brain," said Tulasi Jinka, lead author and IAB post-doctoral fellow in Drew's lab.

The receptors can be regulated by a simple cup of coffee. A caffeine molecule is similar enough in structure to adenosine that it binds to the receptors and effectively stops or reverses the onset of drowsiness. Jinka and Drew wanted to know what substances trip the squirrels' switch to start to hibernate.

"We devised an experiment in which non-hibernating arctic ground squirrels were given a substance that stimulated adenosine receptors in their brains. We expected the substance to induce hibernation," Drew said. "We also gave a substance similar to caffeine to arouse hibernating ground squirrels."

The non-hibernating squirrels were tested three times during one year. They were tested during the summer when they were not hibernating, again early in their hibernation season and a third time mid-way through the hibernation season. If animals were hibernating before the test Jinka woke them up to see if the substance would cause them to go back into hibernation. To ensure that his expectations did not influence the results he delivered a placebo in the same manner as the drug and did not know which solution contained the active substance when he conducted the experiments.

Torpor was induced in all six of the squirrels awoken during mid-hibernation season, but in only two of the six from the early hibernation season group and in none during the summer season. The caffeine-like substance reversed torpor in all of the hibernating squirrels.

"We show for the first time that activation of the adenosine receptors is sufficient to induce torpor in arctic ground squirrels during their hibernation season," Jinka said, who conducted this experiment while he was a graduate student.

What Jinka and Drew don't yet know is how season causes the receptors to become increasingly sensitive to adenosine as the time of hibernation progresses.

Jinka and Drew are expanding their adenosine research to rats, which more closely resemble the physiology of humans. "Rats allow us to move toward being able to apply this research to humans," Jinka said.

Email or share this story:

Saturday, September 3, 2011

Specialized regulatory T cell stifles antibody production centers: Discovery has potential implications for cancer, autoimmune disease

ScienceDaily (July 25, 2011) — A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, a team led by scientists at The University of Texas MD Anderson Cancer Center reported online in the journal Nature Medicine.See Also:Health & MedicineLymphomaImmune SystemStem CellsBrain TumorCancerLung CancerReferenceNatural killer cellT cellLymph nodeHeat shock protein

"Regulatory T cells prevent unwanted or exaggerated immune system responses, but the mechanism by which they accomplish this has been unclear," said paper senior author Chen Dong, Ph.D., professor in MD Anderson's Department of Immunology and director of the Center for Inflammation and Cancer.

"We've identified a molecular pathway that creates a specialized regulatory T cell, which suppresses the reaction of structures called germinal centers. This is where immune system T cells and B cells interact to swiftly produce large quantities of antibodies," Dong said.

The discovery of the germinal center off-switch, which comes two years after Dong and colleagues identified the mechanisms underlying a helper T cell that activates the centers, has potential implications for cancer and autoimmune diseases.

"In some types of cancer, the presence of many regulatory T cells is associated with poor prognosis," Dong said. "The theory is those cells suppress an immune system response in the tumor's microenvironment that otherwise might have attacked the cancer."

However, in B cell lymphomas, overproliferation and mutation of B cells are the problems, Dong said. Hitting the regulatory T cell off-switch might help against lymphomas and autoimmune diseases, while blocking it could permit an immune response against other cancers.

Antibody production central

Germinal centers are found in the lymph nodes and the spleen. They serve as gathering points for B and T cell lymphocytes, infection-fighting white blood cells.

When the adaptive immune system detects an invading bacterium or virus, B cells present a piece of the invader, an antigen, to T cells. The antigen converts a naïve T cell to a helper T cell that secretes cytokines, which help the B cells expand and differentiate into specialized antibodies to destroy the intruder.

"Germinal centers have mostly B cells with a few helper T cells to regulate them. The B cells mutate to make high-affinity antibodies and memory B cells for long-term immunity. The cell population in the germinal center structures replicates in an average of several hours, one of the fastest rates of cell replication known in mammals," Dong said.

Tracking down specialized T cell

In the Nature Medicine paper, Dong and colleagues found that a subgroup of regulatory T cells that expresses two genes, Bcl-6 and CXCR5, moves into germinal centers in both mice and humans, where they have access to B cells.

(Bcl-6 produces a protein called a transcription factor, which moves into the cell nucleus to regulate other genes. CXCR5 is a receptor protein for a signaling molecule called CXCL13.)

They also found that the Bcl-6/CXCR5 T cells aren't produced in the thymus, with other T cells, but are generated by regulatory T cell precursor cells that express Foxp3, another transcription factor.

Knocking out the regulatory T cells that express all three proteins in mice resulted in increased germinal center production of antibodies. They named this key T cell the T follicular regulatory cell, or Tfr.

In a 2009 paper in the journal Science, the researchers found that naïve T cells that expressed Bcl-6 and CXCR5 also gathered in the B cell zone of germinal centers. Expression of Bcl6 converted the T cell into a T follicular helper (Tfh) cell that launches antibody production in the germinal centers.

With Tfr turning germinal centers off and Tfh turning them on, we could potentially regulate antibody production, Dong noted. Increasing Tfr production could be a new approach to treating autoimmune inflammatory disorders, such as lupus and rheumatoid arthritis.

The team's research was funded by grants from the National Institutes of Health, the Leukemia and Lymphoma Society, MD Anderson, the American Heart Association, Doris Duke Charitable Foundation Clinical Scientist Development Award and the China Ministry of Science and Technology Protein Science Key Research Project.

Co-authors with Dong are first author Yeonseok Chung, Ph.D., Shinya Tanaka, Ph.D., Roza Nurieva, Ph.D., Gustavo Martinez, Yi-Hong Wang and Joseph Reynolds, Ph.D., of MD Anderson's Department of Immunology and the Center for Cancer Immunology; Chung also is with The University of Texas Health Science Center at Houston Institute of Molecular Medicine; Seema Rawal and Sattva Neelapu, M.D., of MD Anderson's Department of Lymphoma and Myeloma, also of the Center for Cancer Immunology; and Ziao-hui Zhou, M.D., Hui-min Fan, M.D., and Zhong-ming Liu, M.D., of Shanghai Dong Fang Hospital, Shanghai, China.

Email or share this story: